73/100BMetLife stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for MetLife is 108.63, 6.4% above the current price of 102.07. Their targets range from 103.00 to 112.00.
Of the 12 firms that rated MetLife in the past 12 months, 11 rate it buy or strong buy, 1 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 103.00 to 112.00, with an average of 108.63.
| Buy | 11 | |
| Hold | 1 | |
| Sell | 0 |
12-month price target
| Highest target | 112.00 |
| Average target | 108.63 |
| Lowest target | 103.00 |
| Current price | 102.07 |
MetLife price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their MetLife price target and rating?
How analysts rate MetLife, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
11 of 12 firms rate it buy now, against 8 of 9 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
MetLife analyst upgrades, downgrades and price targets
The latest rating change came on 22 September 2026, when Piper Sandler upgraded MetLife from Neutral to Overweight. Its price target is 110.00, from 90.00. The most recent new target came from Mizuho Securities on 9 November 2026: 112.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 9 Nov 2026 | Mizuho Securities Yaron Kinar | — | 109.00 → 112.00 | +2.8% | 98.27 |
| 7 Oct 2026 | Mizuho Securities Yaron Kinar | Reiterated · Outperform | 95.00 → 109.00 | +14.7% | 97.16 |
| 7 Oct 2026 | Barclays | Reiterated · Overweight | 97.00 → 111.00 | +14.4% | 97.16 |
| 6 Oct 2026 | UBS Michael Ward | Reiterated · Buy | 105.00 → 110.00 | +4.8% | 96.88 |
| 22 Sept 2026 | Piper Sandler Paul Newsome | Upgraded · Neutral → Overweight | 90.00 → 110.00 | +22.2% | 96.64 |
| 24 Aug 2026 | Morgan Stanley Bob Huang | Reiterated · Overweight | 103.00 → 111.00 | +7.8% | 95.75 |
| 19 Aug 2026 | Wells Fargo | Reiterated · Overweight | 95.00 → 109.00 | +14.7% | 96.73 |
| 6 Aug 2026 | Barclays | Reiterated · Overweight | 94.00 → 97.00 | +3.2% | 96.26 |
| 15 Jul 2026 | Atlantic Equities | — | 103.00 | — | 92.44 |
| 10 Jul 2026 | Jefferies Suneet Kamath | Reiterated · Buy | 103.00 | — | 91.15 |
| 8 Jul 2026 | UBS Michael Ward | Reiterated · Buy | 102.00 → 105.00 | +2.9% | 90.27 |
| 7 Jul 2026 | Barclays Alex Scott | Reiterated · Overweight | 93.00 → 94.00 | +1.1% | 90.46 |
| 6 Jul 2026 | Morgan Stanley | Reiterated · Overweight | 93.00 → 103.00 | +10.8% | 90.93 |
| 24 Jun 2026 | Piper Sandler | Reiterated · Neutral | 86.00 → 90.00 | +4.7% | 88.03 |
| 26 May 2026 | Piper Sandler | Reiterated · Neutral | 84.00 → 86.00 | +2.4% | 84.06 |
| 21 May 2026 | Morgan Stanley Bob Huang | Reiterated · Overweight | 101.00 → 93.00 | -7.9% | 83.50 |
| 12 May 2026 | Wells Fargo | Reiterated · Overweight | 97.00 → 95.00 | -2.1% | 77.98 |
| 8 May 2026 | Mizuho Securities Yaron Kinar | — | 93.00 → 95.00 | +2.2% | 78.82 |
| 7 May 2026 | Barclays Alex Scott | Reiterated · Overweight | 90.00 → 93.00 | +3.3% | 80.16 |
| 13 Apr 2026 | Mizuho Securities Yaron Kinar | Reiterated · Outperform | 100.00 → 93.00 | -7.0% | 74.63 |
| 9 Apr 2026 | Evercore ISI | Reiterated · In Line | 95.00 → 96.00 | +1.1% | 74.65 |
| 9 Apr 2026 | UBS | Reiterated · Buy | 98.00 → 102.00 | +4.1% | 74.65 |
| 12 Feb 2026 | Mizuho Securities | — | 102.00 → 100.00 | -2.0% | 78.89 |
| 10 Feb 2026 | Evercore ISI Thomas Gallagher | — | 97.00 → 95.00 | -2.1% | 77.92 |
| 5 Feb 2026 | UBS | Reiterated · Buy | 94.00 → 98.00 | +4.3% | 78.01 |
| 14 Jan 2026 | Mizuho Securities | — | 101.00 → 102.00 | +1.0% | 77.08 |
| 13 Jan 2026 | Wells Fargo Elyse Greenspan | Reiterated · Overweight | 97.00 | — | 78.32 |
| 8 Jan 2026 | UBS | Reiterated · Buy | 94.00 | — | 79.79 |
| 8 Jan 2026 | Barclays | — | 98.00 → 90.00 | -8.2% | 79.47 |
| 6 Jan 2026 | Evercore ISI | — | 97.00 | — | 81.77 |
| 15 Dec 2025 | Mizuho Securities | — | 101.00 | — | 82.62 |
| 15 Dec 2025 | Morgan Stanley | — | 97.00 → 101.00 | +4.1% | 83.22 |
MetLife EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect MetLife's EPS to grow 37.1% a year until 2028. Over the last 5 years it fell 3.3% a year, and over the last 3 years it fell 8.7%.
Analysts expect MetLife's revenue to grow 4.1% a year until 2028, about as fast as over the last 5 years (2.6% a year) and the last 3 years (4.3%).
Revenue
EPS
Does MetLife beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 4.6% off the result, either way, and their revenue estimate 5.0%, over the last 12 quarters.
- EPS beats
- 77 / 106
- Revenue beats
- 84 / 106
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +1.3%
- Since
- August 2000
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 4 Nov 2026 | 2.77 | 2.78 | +0.4% | 19.86B | 20.52B | +3.4% |
| Q2 FY2026 | 5 Aug 2026 | 2.30 | 2.43 | +5.7% | 19.67B | 19.08B | -3.0% |
| Q1 FY2026 | 6 May 2026 | 2.27 | 2.42 | +6.6% | 19.49B | 19.68B | +1.0% |
| Q4 FY2025 | 4 Feb 2026 | 2.34 | 2.58 | +10.3% | 27.22B | 23.81B | -12.5% |
| Q3 FY2025 | 5 Nov 2025 | 2.31 | 2.34 | +1.3% | 18.64B | 16.88B | -9.4% |
| Q2 FY2025 | 6 Aug 2025 | 2.15 | 2.02 | -6.0% | 18.53B | 17.34B | -6.4% |
| Q1 FY2025 | 30 Apr 2025 | 2.00 | 1.96 | -2.0% | 18.37B | 18.28B | -0.5% |
| Q4 FY2024 | 5 Feb 2025 | 2.11 | 2.08 | -1.4% | 19.50B | 18.38B | -5.8% |
| Q3 FY2024 | 30 Oct 2024 | 2.17 | 1.95 | -10.1% | 18.66B | 18.44B | -1.2% |
| Q2 FY2024 | 31 Jul 2024 | 2.10 | 2.28 | +8.6% | 18.57B | 17.82B | -4.0% |
| Q1 FY2024 | 1 May 2024 | 1.84 | 1.83 | -0.5% | 17.73B | 16.06B | -9.4% |
| Q4 FY2023 | 31 Jan 2024 | 1.88 | 1.93 | +2.7% | 18.46B | 19.03B | +3.1% |
MetLife stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If MetLife's earnings keep growing at the 11.6% a year analysts expect to FY2028, it would earn about 15.41 a share in FY2030. At the P/E it has traded at over the last five years (8.1 to 36.3) that is 125.06 to 559.94 a share, or 254.81 at its average P/E of 16.5. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 10.24 | 83.07 | 169.24 | 371.91 |
| FY2027 | 11.16 | 90.60 | 184.58 | 405.62 |
| FY2028 | 12.37 | 100.41 | 204.57 | 449.54 |
| FY2029 (extrapolated) | 13.81 | 112.06 | 228.31 | 501.72 |
| FY2030 (extrapolated) | 15.41 | 125.06 | 254.81 | 559.94 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 11.6% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (8.1, 16.5, 36.3).
Is MetLife stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
MetLife's P/E of 13.2 is around the middle of its 5-year range (6.5 to 40.5, median 14.4). It is in line with its own history. At the median P/E of its peers (12.7 × EPS of 7.72), MetLife's fair value is 98.31, close to the price of 102.07. Its forward P/E, on the consensus for FY2026, is 10.0.
Fair value on the peers is the median P/E of the US companies of its industry closest in size times its earnings per share of the last twelve months; the ends of the bar are the same earnings at the lowest and highest peer P/E (10.5 and 17.4). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 13.22
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 14.37
- Five-year P/E range
- 6.5 – 40.5
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 9.97
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.14
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +6.4%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 235.690 | 464.49205Price 235.69627 | +97.1% | |
| 28.860 | 56.2634Price 28.8696 | +94.9% | |
| 199.110 | 384.58163Price 199.112,644 | +93.1% | |
| 123.990 | 237.24178Price 123.99297 | +91.3% | |
| 157.820 | 297.58169Price 157.82471 | +88.6% | |
| 162.670 | 305.52160Price 162.67396 | +87.8% | |
| 216.610 | 405.38304Price 216.61507 | +87.1% |
Furthest below the fair value on each stock's page, updated every day.